Review Article | Published:

Interstitial cystitis and systemic autoimmune diseases

Nature Clinical Practice Urology volume 4, pages 484491 (2007) | Download Citation

Subjects

Abstract

The cause of interstitial cystitis, a chronic disease that affects the bladder, is unknown. Autoantibodies, such as those against nuclear and bladder epithelium antigens, have been found in patients with interstitial cystitis, but these are likely to be secondary to the disease. No data support a direct causal role of autoimmune reactivity in the pathogenesis of interstitial cystitis. Indirect evidence, however, does support a possible autoimmune nature of interstitial cystitis, such as the strong female preponderance and the clinical association between interstitial cystitis and other known autoimmune diseases within patients and families. The strongest association occurs between interstitial cystitis and Sjögren's syndrome. Increasing evidence suggests a possible role of autoantibodies to the muscarinic M3 receptor in Sjögren's syndrome. The M3 receptor is also located on the detrusor muscle cells of the bladder and mediates cholinergic contraction of the urinary bladder and other smooth muscle tissues. Autoantibodies to the M3 receptor might be important in both the early noninflammatory and the late inflammatory features of interstitial cystitis.

Key points

  • The association within patients and families between interstitial cystitis (IC) and known autoimmune diseases and a female preponderance suggest an autoimmune nature of IC, although direct evidence clearly showing autoimmune mechanisms is lacking

  • The strongest association is between IC and Sjögren's syndrome, a disease in which autoantibodies to the muscarinic M3 receptor on exocrine cells are important in the pathogenesis

  • Muscarinic M3 receptors are also expressed on detrusor smooth muscle cells, where they mediate cholinergic contraction of the urinary bladder

  • Autoantibodies that target muscarinic M3 receptors might therefore have a role in the pathogenesis of IC

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. (2004) Primary evaluation of patients suspected of having interstitial cystitis (IC). Eur Urol 45: 662–669

  2. 2.

    et al. (2001) Nonbladder related symptoms in patients with interstitial cystitis. J Urol 166: 557–561

  3. 3.

    et al. (2000) Interstitial cystitis in Japan. BJU Int 86: 634–637

  4. 4.

    et al. (1999) Epidemiology of interstitial cystitis: a population based study. J Urol 161: 549–552

  5. 5.

    and (2005) Prevalence of interstitial cystitis symptoms in women: a population based study in the primary care office. J Urol 174: 2231–2234

  6. 6.

    et al. (2005) Prevalence of clinically confirmed interstitial cystitis in women: a population based study in Finland. J Urol 174: 581–583

  7. 7.

    et al. (2006) Prevalence and correlates for interstitial cystitis symptoms in women participating in a health screening project. Eur Urol 51: 803–808

  8. 8.

    et al. (2000) A prospective study of interstitial cystitis: results of longitudinal followup of the interstitial cystitis data base cohort. The Interstitial Cystitis Data Base Study Group. J Urol 163: 1434–1439

  9. 9.

    et al. (1994) Prevalence of interstitial cystitis in the United States. J Urol 151: 423A

  10. 10.

    et al. (2002) The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21: 167–178

  11. 11.

    et al. (2002) Interstitial cystitis: an update. Curr Opin Urol 12: 321–332

  12. 12.

    et al. (1993) Sjögren's syndrome in patients with interstitial cystitis. J Rheumatol 20: 962–966

  13. 13.

    (2003) Sjögren's syndrome in patients with interstitial cystitis. Preliminary results in 100 patients. Int J Urol 10 (Suppl): S69

  14. 14.

    et al. (1997) Interstitial cystitis: unexplained associations with other chronic disease and pain syndromes. Urology 49 (5A Suppl): S52–S57

  15. 15.

    (2003) Significance of complications of allergic diseases in young patients with interstitial cystitis. Int J Urol (10 Suppl): S56–S58

  16. 16.

    et al. (2003) Intercurrent autoimmune conditions in classic and non-ulcer interstitial cystitis. Scand J Urol Nephrol 37: 60–63

  17. 17.

    and (1997) Autoimmunity and interstitial cystitis. In Interstitial Cystitis, 47–52 (Ed. Sant GR) Philadelphia: Lippincott-Raven

  18. 18.

    et al. (1994) Autoantibodies in interstitial cystitis. J Urol 151: 587–592

  19. 19.

    et al. (1997) Urine autoantibodies in interstitial cystitis. J Urol 157: 1083–1087

  20. 20.

    et al. (2006) Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus 15: 308–318

  21. 21.

    et al. (1984) Involvement of the urinary bladder in systemic lupus erythematosus. A pathologic study. J Rheumatol 11: 208–210

  22. 22.

    et al. (1977) Sjögren's syndrome in SLE: Part 2. An examination of the clinical significance of Sjögren's syndrome by comparison of its frequency in typical and atypical forms of SLE, overlap syndromes and scleroderma. N Z Med J 86: 376–379

  23. 23.

    et al. (1990) Sjögren's syndrome in systemic lupus erythematosus. J Rheumatol 17: 201–204

  24. 24.

    et al. (2001) Sicca symptoms and secondary Sjögren's syndrome in systemic lupus erythematosus: comparison with rheumatoid arthritis and correlation with disease variables. Ann Rheum Dis 60: 1103–1109

  25. 25.

    et al. (1990) Subacute cutaneous lupus erythematosus in Greece. A clinical, serological and genetic study. Ann Med Interne (Paris) 141: 421–424

  26. 26.

    et al. (2004) Is there an ethnic difference in the prevalence of lupus cystitis? A report of six cases. Lupus 13: 263–269

  27. 27.

    et al. (2007) Diagnostic accuracy of the FIDIS multiplex fluorescent microsphere immunodetection system for anti-extractable nuclear antigen (ENA) antibodies in connective tissue diseases. Clin Chem Lab Med 45: 505–512

  28. 28.

    et al. (2005) Clinical utility of the anti-CCP assay: experiences with 700 patients. Ann NY Acad Sci 1050: 314–318

  29. 29.

    et al. (2005) Diagnostic value of anti-cyclic citrullinated peptide antibodies to detect rheumatoid arthritis in patients with Sjögren's syndrome. Ann Rheum Dis 64: 160–162

  30. 30.

    and (1987) Concurrence of rheumatoid arthritis and systemic lupus erythematosus: report of 11 cases. Ann Rheum Dis 46: 853–858

  31. 31.

    et al. (2005) Familial aggregation of systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune diseases in 1,177 lupus patients from the GLADEL cohort. Arthritis Rheum 52: 1138–1147

  32. 32.

    et al. (1987) Secondary Sjogren's syndrome in rheumatoid arthritis. J Rheumatol 14: 1098–1103

  33. 33.

    et al. (2006) Lower urinary tract symptoms in female patients with rheumatoid arthritis. Scand J Rheumatol 35: 96–101

  34. 34.

    et al. (1984) Primary Sjögren syndrome: clinical and immunopathologic features. Semin Arthritis Rheum 14: 77–105

  35. 35.

    et al. (1992) Antiphospholipid antibodies and HLA associations in primary Sjögren's syndrome. Ann Rheum Dis 51: 495–498

  36. 36.

    et al. (2004) Abacterial prostatitis and primary biliary cirrhosis with Sjögren's syndrome. Mod Rheumatol 14: 70–72

  37. 37.

    et al. (2006) Atypical autoantibodies in patients with primary Sjögren syndrome: clinical characteristics and follow-up of 82 cases. Semin Arthritis Rheum 35: 312–321

  38. 38.

    et al. (2001) Use of muscarinic agonists in the treatment of Sjögren's syndrome. Clin Immunol 101: 249–263

  39. 39.

    et al. (1998) Transfer of human serum IgG to nonobese diabetic Igµnull mice reveals a role for autoantibodies in the loss of secretory function of exocrine tissues in Sjögren's syndrome. Proc Natl Acad Sci USA 95: 7538–7543

  40. 40.

    et al. (1998) Autoantibodies against lacrimal gland M3 muscarinic acetylcholine receptors in patients with primary Sjögren's syndrome. Invest Ophthalmol Vis Sci 39: 151–156

  41. 41.

    and (1999) New concepts for the development of autoimmune exocrinopathy derived from studies with the NOD mouse model. Arch Oral Biol 44 (Suppl 1): S21–S25

  42. 42.

    et al. (2001) Autoantibodies in primary Sjögren's syndrome: new insights into mechanisms of autoantibody diversification and disease pathogenesis. Autoimmunity 34: 123–132

  43. 43.

    et al. (2006) Antimuscarinic antibodies in primary Sjögren's syndrome reversibly inhibit the mechanism of fluid secretion by human submandibular salivary acinar cells. Arthritis Rheum 54: 1165–1173

  44. 44.

    et al. (2005) Clinical associations of autoantibodies to human muscarinic acetylcholine receptor 3 (213–228) in primary Sjögren's syndrome. Rheumatology (Oxford) 44: 1021–1025

  45. 45.

    et al. (2005) Muscarinic acetylcholine receptor autoantibodies in patients with Sjögren's syndrome. Ann Rheum Dis 64: 510–511

  46. 46.

    et al. (2006) Altered peptide ligands regulate muscarinic acetylcholine receptor reactive T cells of patients with Sjögren's syndrome. Ann Rheum Dis 65: 269–271

  47. 47.

    and (1991) Effects of pilocarpine on salivary flow in patients with Sjögren's syndrome. Oral Surg Oral Med Oral Pathol 72: 545–549

  48. 48.

    et al. (1999) Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. Arch Intern Med 159: 174–181

  49. 49.

    and (2000) Interstitial cystitis: a review of immunological aspects of the aetiology and pathogenesis, with a hypothesis. BJU Int 85: 995–999

  50. 50.

    et al. (2000) Lower urinary tract symptoms in patients with Sjögren's syndrome and systemic lupus erythematosus. Int Urogynecol J Pelvic Floor Dysfunct 11: 84–86

  51. 51.

    et al. (2003) Interstitial cystitis-like urinary symptoms among patients with Sjögren's syndrome: a population-based study in Finland. Am J Med 115: 62–65

  52. 52.

    et al. (1997) Prevalence of Sjögren's syndrome in a closed rural community. Ann Rheum Dis 56: 521–525

  53. 53.

    et al. (1998) Sjögren's syndrome: a community-based study of prevalence and impact. Br J Rheumatol 37: 1069–1076

  54. 54.

    et al. (1994) Sjögren's syndrome, keratoconjunctivitis sicca and focal lymphocytic sialoadenitis in patients with interstitial cystitis. In Sjögren's Syndrome—State of the Art Proceedings of the Fourth International Symposium, 347–349 (Eds Homma M et al.) Amsterdam: Kugler Publications

  55. 55.

    et al. (2002) Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61: 554–558

  56. 56.

    et al. (2006) Qualitative and quantitative expression profile of muscarinic receptors in human urothelium and detrusor. J Urol 176: 1673–1678

  57. 57.

    et al. (1995) Expression of muscarinic M3-receptors coupled to inositol phospholipid hydrolysis in human detrusor cultured smooth muscle cells. J Urol 154: 1241–1245

  58. 58.

    et al. (2006) Localization of M2 and M3 muscarinic receptors in human bladder disorders and their clinical correlations. J Urol 176: 367–373

  59. 59.

    et al. (2005) Muscarinic receptor subtypes in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: changes in ageing. Br J Pharmacol 144: 1089–1099

  60. 60.

    (2006) Muscarinic receptors in the bladder: from basic research to therapeutics. Br J Pharmacol 147 (Suppl 2): S80–S87

  61. 61.

    et al. (2004) Passive transfer of Sjögren's syndrome IgG produces the pathophysiology of overactive bladder. Arthritis Rheum 50: 3637–3645

  62. 62.

    and (1990) Signs of Sjögren's syndrome in a patient with myasthenia gravis. Acta Neurol Scand 81: 179–180

  63. 63.

    et al. (2004) Pathophysiology of myasthenia gravis. Semin Neurol 24: 21–30

  64. 64.

    and (2003) Thyrotropin receptor autoantibodies (TSHRAbs): epitopes, origins and clinical significance. Autoimmunity 36: 331–337

  65. 65.

    et al. (2006) Human detrusor smooth muscle cells release interleukin-6, interleukin-8, and RANTES in response to proinflammatory cytokines interleukin-1β and tumor necrosis factor-α. Urology 67: 214–219

  66. 66.

    et al. (2007) RANTES mediates TNF-dependent lamina propria mast cell accumulation and barrier dysfunction in neurogenic cystitis. Am J Physiol Renal Physiol 292: F1372–F1379

  67. 67.

    et al. (2007) The mast cell in interstitial cystitis: role in pathophysiology and pathogenesis. Urology 69 (4 Suppl): 34–40

  68. 68.

    (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40: 1725

Download references

Author information

Affiliations

  1. JP van de Merwe is a Consultant of Internal Medicine and Clinical Immunology at the Erasmus MC, University Medical Center, Rotterdam, The Netherlands.

    • Joop P van de Merwe

Authors

  1. Search for Joop P van de Merwe in:

Competing interests

The author declares no competing financial interests.

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/ncpuro0874

Further reading